Embecta Corp. (EMBC)

Market Cap	350.72M -55.9%
Revenue (ttm)	1.02B -7.6%
Net Income	87.50M +4.7%
EPS	1.47 +3.4%
Shares Out	56.66M
PE Ratio	4.21
Forward PE	3.85
Dividend	$0.04 (0.65%)
Ex-Dividend Date	Aug 27, 2026

Volume	659,498
Open	6.28
Previous Close	6.25
Day's Range	6.13 - 6.36
52-Week Range	2.77 - 14.91
Beta	0.83
Analysts	Hold
Price Target	4.00 (-35.38%)
Est. Earnings	Nov 24, 2026

About EMBC

Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company’s products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient’s diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1924
• Employees: 1,850
• Stock Exchange: Nasdaq
• Ticker Symbol: EMBC
• Website: https://www.embecta.com

Financial Performance

In fiscal year 2025, Embecta's revenue was $1.08 billion, a decrease of -3.80% compared to the previous year's $1.12 billion. Earnings were $95.40 million, an increase of 21.84%.

Analyst Summary

According to 4 analysts, the average rating for EMBC stock is "Hold." The 12-month stock price target is $4.0, which is a decrease of -35.38% from the latest price.

Price Target

$4.0

(-35.38% downside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Nov 3, 2026

Data Sources Report a data error